Volastra

Volastra develops therapeutics for cancer treatment, focusing on compounds that target chromosomal instability and related pathways to inhibit genomic instability and disease progression. The company is also developing proprietary imaging technologies to identify chromosomal instability cancers for patient stratification. Founded in 2019 and headquartered in New York City, Volastra has raised approximately $117.3M in Series B funding from investors including Polaris Partners, Droia, Arch Venture Partners, Vida Ventures, Catalio Capital Management, Lilly, Cornell University, and B Capital. The company targets chromosomal instability, a hallmark of aggressive cancers that drives tumor evolution, metastasis, and therapy resistance. By developing drugs that specifically address the mechanisms underlying chromosomal instability, Volastra aims to create new treatment options for patients with cancers that have limited therapeutic alternatives, particularly in indications where chromosomal instability drives poor outcomes.